RxDoctor Payments Data

Brett Norman, MD

Critical Care Medicine · Nashville, TNNPI 1881850667

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Medtronic at 58.7% of the total. Reporting peaked in 2023 at $1,116 and has fallen 81.4% since, to $208 in 2025.

$1,594in general payments, 2019–2025

Across 32 payments — averaging $49.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$935
  • Noah Medical Corporation$133
  • Sanofi-aventis U.S. LLC$95
  • Sanofi$74
  • Pulmonx Corporation$68
  • Regeneron Healthcare Solutions, Inc.$52
  • plus $236 from 9 others

What the payments were for

  • Travel & lodging$90757%
  • Food & beverage$55935%
  • Education$1278%

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,594 in reported general payments places this provider in the 65th percentile of 141 critical care medicine providers in Tennessee.

See all critical care medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$19,961
Medicare patients
85
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$54,224
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$24,195
EliquisApixaban19$12,395
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$11,218
Breo ElliptaFluticasone/Vilanterol17$6,855
SymbicortBudesonide/Formoterol Fumarate30$6,852
Advair HfaFluticasone Propion/Salmeterol13$5,411
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$3,960
Varenicline Tartrate13$2,523
Albuterol Sulfate HfaAlbuterol Sulfate66$1,185
Montelukast Sodium50$513
Fluticasone Propionate24$272
Prednisone47$157
Omeprazole12$124
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$19$72,297117 claims
AstraZenecaBreztri Aerosphere, Symbicort$42$31,04669 claims
PfizerEliquis$23$12,39519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 141 critical care medicine providers in Tennessee.

Other critical care medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →